Fresh jolt to Bayer in Nexavar drug case

Posted on February 9 2010 by admin

In another jolt to the German pharma major Bayer Corporation, the Division Bench of the Delhi High Court on Tuesday dismissed its petition seeking to restrain Drug Controller General of India from giving approval to the domestic producer Cipla for production and sale of Soranib the generic version of anti-cancer drug Nexavar. A Division Bench comprising Chief Justice AP Shah and Justice S Muralidhar upheld the earlier single Bench judgement given out by Ravindra Bhatt and rejected the allegations of Bayer terming Cipla s generic version drug as spurious. Cipla is yet to start production of the generic version of the …

You May Like These Articles




You May Like These Articles

Leave a Reply